Logotype for Diamyd Medical

Diamyd Medical (DMYD) investor relations material

Diamyd Medical Status Update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Diamyd Medical
Status Update summary14 Nov, 2025

Disease overview and unmet need

  • Type 1 diabetes affects around 9 million people globally, with 300,000-500,000 new diagnoses each year.

  • The disease is caused by an autoimmune attack on insulin-producing beta cells, leading to insulin deficiency and serious complications.

  • HLA genotyping helps identify individuals at higher risk due to genetic predisposition.

Advances in disease understanding and measurement

  • C-peptide is a key marker for measuring endogenous insulin production and is central to clinical trial endpoints.

  • Preserving C-peptide is crucial for maintaining metabolic control and reducing complications.

  • Precision medicine is guiding the development of targeted therapies based on genetic and immunological profiles.

Diamyd Medical’s positioning and clinical development

  • Diamyd Medical is conducting the first precision medicine-based phase III trial in Type 1 diabetes, targeting patients identified by HLA genetics.

  • Their GAD65-based therapy is the only antigen-specific immunotherapeutic in phase III, aiming to reprogram the immune system without broad immunosuppression.

  • The phase III trial includes patients aged 12-28, with potential to expand to younger children in future studies.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Diamyd Medical earnings date

Logotype for Diamyd Medical
Q1 202629 Jan, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Diamyd Medical earnings date

Logotype for Diamyd Medical
Q1 202629 Jan, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Diamyd Medical AB is a biotechnology company headquartered in Stockholm, Sweden, specializing in the development of immune modifying therapies for diabetes. The company is actively engaged in the pharmaceutical development field, focusing on two innovative disease-modifying drugs: Diamyd, an antigen-specific immunotherapy, and Remygen, an oral regenerative and immunomodulatory therapeutic. These drugs are undergoing clinical trials and are designed to address the underlying causes of diabetes, including dysfunction and loss of the pancreas's insulin-producing cells. Diamyd Medical operates a manufacturing facility in Umeå and leverages a global network of clinics, researchers, and production units for its development efforts. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq First North.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage